MBX Stock Summary and Trading Ideas (MBX Biosciences | NASDAQ:MBX)

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

MBX Biosciences trades on the NASDAQ stock market under the symbol MBX.

As of August 18, 2026, MBX stock price declined to $66.52 with 532,723 million shares trading.

MBX has a beta of 1.46, meaning it tends to be more sensitive to market movements. MBX has a correlation of 0.03 to the broad based SPY ETF.

MBX has a market cap of $3.20 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that MBX belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.

MBX has outperformed the market in the last year with a return of +356.6%, while the SPY ETF gained +20.5%. In the last 3 month period, MBX beat the market returning +114.7%, while SPY returned +4.2%. However, in the most recent 2 weeks MBX has underperformed the stock market by returning -5.9%, while SPY returned -0.5%.

MBX support price is $64.84 and resistance is $71.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBX shares will trade within this expected range on the day.